Dechra Pharmaceuticals PLC (GB:DPH)
LSE:DPH

Dechra Pharmaceuticals Stock Price & Analysis

3 Followers

DPH Stock Chart & Stats

Day’s Range0p - 0p
52-Week Range2,457.30p - 5,314.46p
Previous Close2,790p
Volume16.55K
Average Volume (3M)475.38K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)57.3
Beta1.21
Next EarningsFeb 27, 2023
EPS EstimateN/A
Dividend Yield0.45 (1.61%)
EPS (TTM)0.54
Shares Outstanding113,824,796
R-Squared0.05
Standard Deviation0.08
10 Day Avg. Volume360,330
30 Day Avg. Volume475,384
Price to Book (P/B)-49.85
Price to Sales (P/S)6.07
Price to Cash Flow (P/CF)24.60
P/FCF Ratio3528.60
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside55.13% Upside
Rating ConsensusStrong Buy
Alpha0.02
Number of Analyst Covering4


DPH FAQ

What was Dechra Pharmaceuticals’s price range in the past 12 months?
Dechra Pharmaceuticals lowest stock price was 2457.30p and its highest was 5314.46p in the past 12 months.
    What is Dechra Pharmaceuticals’s market cap?
    Currently, no data Available
    When is Dechra Pharmaceuticals’s upcoming earnings report date?
    Dechra Pharmaceuticals’s upcoming earnings report date is Feb 27, 2023 which is in 85 days.
      How were Dechra Pharmaceuticals’s earnings last quarter?
      Dechra Pharmaceuticals released its earnings results on Sep 05, 2022. The company reported 0.161p earnings per share for the quarter, beating the consensus estimate of N/A by 0.161p.
        Is Dechra Pharmaceuticals overvalued?
        According to Wall Street analysts Dechra Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Dechra Pharmaceuticals pay dividends?
          Dechra Pharmaceuticals pays a Annually dividend of 32.89p which represents an annual dividend yield of 1.61%. Dechra Pharmaceuticals’s last Annually dividend payment was on Nov 18, 2022. Dechra Pharmaceuticals’s upcoming ex-dividend date is Oct 27, 2022
            What is Dechra Pharmaceuticals’s EPS estimate?
            Dechra Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Dechra Pharmaceuticals have?
            Dechra Pharmaceuticals has 113,824,800 shares outstanding.
              What happened to Dechra Pharmaceuticals’s price movement after its last earnings report?
              Dechra Pharmaceuticals reported an EPS of 0.161p in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -10.583%.
                Which hedge fund is a major shareholder of Dechra Pharmaceuticals?
                Currently, no hedge funds are holding shares in GB:DPH

                ---

                Dechra Pharmaceuticals Stock Smart Score

                6
                Neutral
                1
                2
                3
                4
                5
                6
                7
                8
                9
                10

                Technicals

                SMA
                Negative
                20 days / 200 days
                Momentum
                -43.69%
                12-Months-Change

                Fundamentals

                Return on Equity
                8.96%
                Trailing 12-Months
                Asset Growth
                6.52%
                Trailing 12-Months
                The Dechra Pharmaceuticals Holdings stock analysis is based on the TipRanks Smart Score which is derived from 6 unique data sets including Analyst recommendations, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                Learn more about TipRanks Smart Score

                Company Description

                Dechra Pharmaceuticals PLC

                Dechra Pharmaceuticals PLC is a major drug manufacturing company with a focus on veterinary pharmaceutical products. The company develops, manufactures, and markets its products exclusively for veterinarians globally. Dechra is structured along three segments, including being European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The vast majority of Dechra's revenue is generated in Europe, followed by the U.S. Dechra derives most of its revenue through its Companion Animal Product category, followed by food-producing animal products.

                ---

                Forecast EPS vs Actual EPS


                Similar Stocks
                Company
                Price & Change
                Follow
                AstraZeneca
                GlaxoSmithKline
                Hikma Pharmaceuticals
                Indivior

                Popular Stocks

                ---
                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis